<DOC>
	<DOCNO>NCT00087204</DOCNO>
	<brief_summary>This phase I trial study side effect best dose rebeccamycin analog treat patient relapsed refractory acute myeloid leukemia , myelodysplastic syndrome , acute lymphoblastic leukemia , chronic myelogenous leukemia blast phase . Drugs use chemotherapy , rebeccamycin analog , work different way stop cancer cell divide stop growing die</brief_summary>
	<brief_title>Rebeccamycin Analog Treating Patients With Relapsed Refractory Acute Myeloid Leukemia , Myelodysplastic Syndrome , Acute Lymphoblastic Leukemia , Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose-limiting toxicity rebeccamycin analogue ( XL119 ) patient relapse refractory acute myeloid leukemia , myelodysplastic syndrome , acute lymphoblastic leukemia , chronic myelogenous leukemia blastic phase . OUTLINE : This dose-escalation study . Patients receive rebeccamycin analogue ( XL119 ) IV 1 hour day 1-5 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 1 additional course beyond CR . Patients achieve partial response ( PR ) hematologic improvement ( HI ) receive 2 additional course beyond PR HI . Cohorts 3-6 patient receive escalate dos XL119 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Diagnosis 1 follow : Acute myeloid leukemia Myelodysplastic syndrome , include 1 following : Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia transformation â‰¥ 10 % peripheral blood bone marrow blast Acute lymphoblastic leukemia Chronic myelogenous leukemia blastic phase Relapsed refractory disease , define 1 follow : Failed achieve complete response ( CR ) standard induction regimen Relapsed achieve CR Failed last cytotoxic regimen study entry No alternate , potentially curative option available No known CNS disease Performance status ECOG 02 SGOT SGPT normal Bilirubin normal Creatinine normal No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIVpositive patient normal CD4 count without AIDSdefining disease allow No history allergic reaction attribute compound similar chemical biologic composition rebeccamycin analogue ( XL119 ) No concurrent uncontrolled illness No active ongoing infection No psychiatric illness social situation would preclude study compliance No prior allogeneic stem cell transplantation No concurrent prophylactic hematopoietic colonystimulating factor ( CSF ) No epoetin alfa hematopoietic CSF course 1 study therapy More 7 day since prior cytotoxic chemotherapy except hydroxyurea More 7 day since prior radiotherapy Recovered prior therapy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer agent therapies No concurrent antileukemic agent therapies No concurrent investigational agent therapies No concurrent cytotoxic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>